Open Access<p>Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo</p>
Author(s) -
Yahui Chen,
YiChun Chen,
Chi-Chen Lin,
Yih Shou Hsieh,
Chien-Sheng Hsu,
Meng-Hsuan Hsieh
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s247876
Subject(s) - gemcitabine , apoptosis , propidium iodide , cancer research , cell cycle , pancreatic cancer , pitavastatin , viability assay , chemistry , cell cycle checkpoint , programmed cell death , pharmacology , cancer , biology , statin , medicine , biochemistry
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient's chemotherapeutic initiation. Statins, including pitavastatin, have been indicated to have anticancer effects in numerous human cancer cell lines. Thus, in this study, we hypothesized that a combination of gemcitabine and pitavastatin may have a greater anticancer effect than gemcitabine alone on the human pancreatic carcinoma cell line MIA PaCa-2.